Vertex Pharmaceuticals

Biotech

EMA clears barrier on road to landmark Vertex-CRISPR approval

Vertex and CRISPR have secured European Medicines Agency validation of the approval application for their CRISPR-Cas9 candidate.
Nick Paul Taylor Jan 25, 2023 8:20am

Vertex pays Entrada $224M for preclinical rare disease drug

Dec 8, 2022 9:06am

No pain, only gain for Vertex as FDA greenlights phase 3 trial

Jul 22, 2022 10:59am

Vertex puts up $60M to partner on in vivo gene editing program

Jul 21, 2022 9:10am

Vertex buys ViaCyte for $320M, clearing out T1D competition

Jul 11, 2022 11:45am

Vertex's Type 1 diabetes med back on track after FDA hold lifted

Jul 5, 2022 10:23am